Cour Pharmaceuticals Development Stock

www.courpharma.comHealthcare / BioTech & PharmaFounded: 2012

COUR Pharmaceuticals aims to advance novel therapies that reprogram the immune system for antigen-specific tolerance, focusing on the root of immune-mediated diseases. Their cutting-edge nanoparticle platform diverges from traditional symptom-suppressing treatments, offering a more targeted approach. Collaborating with Takeda on a leading celiac disease therapy, COUR has achieved the first instance of antigen-specific immune tolerance in autoimmune diseases. This breakthrough underscores the potential of their platform to address a wide array of immune and inflammatory conditions.

Register To Buy and Sell Shares

For more details on financing and valuation for Cour Pharmaceuticals Development, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Cour Pharmaceuticals Development’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cour Pharmaceuticals Development.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

John Puisis
Co-Founder, President & Chief Executive Officer
Stephen Miller Ph.D
Co-Founder
Roy First MD
Chief Medical Officer
Brian Bock
Chief Financial Officer
Dannielle Appelhans
Chief Operating Officer
Sarah Longoria
Chief People Officer

Board Members

Chris Dimitropoulos
Alpha Wave Global

Frequently Asked Questions About Cour Pharmaceuticals Development’s Stock

plusminus
Can you buy Cour Pharmaceuticals Development’s stock?
Cour Pharmaceuticals Development is not publicly traded on NYSE or NASDAQ in the U.S. To buy Cour Pharmaceuticals Development’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Cour Pharmaceuticals Development’s stock?
Yes, you can sell stock of a private company like Cour Pharmaceuticals Development. Forge can help you sell your Cour Pharmaceuticals Development stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Cour Pharmaceuticals Development’s stock price?
Cour Pharmaceuticals Development is a privately held company and therefore does not have a public stock price. However, you may access Cour Pharmaceuticals Development’s private market stock price with Forge Data.
plusminus
What is Cour Pharmaceuticals Development’s stock ticker symbol?
Cour Pharmaceuticals Development does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Cour Raises $105M in Series A Round with Backing From Big Pharma
Illinois-based Cour Pharmaceuticals on Tuesday announced that it raised $105 million in Series A funding to help the company advance multiple, wholly-owned candidates. The investment was led by Lumira Ventures and Alpha Wave Ventures and had participation from Bristol Myers Squibb, Pfizer Breakthrough Growth Initiatives and Roche Ventures. Angelini Ventures and the DJRF T1D Fund also participated.
Cour Pharmaceuticals, a biotech taking aim at autoimmune diseases, raises $105 million
The group was developing a sort of Trojan horse that it hoped could be used to treat autoimmune diseases. They had developed polymer nanoparticles that could mimic dying cells, which the immune system won’t attack, but will naturally pull from the bloodstream and throw into the body’s waste collection and recycling systems — the spleen and liver — for disposal. Inside of the polymer nanoparticles, they could hide disease-specific antigen that could begin correcting the immune system’s overreaction to certain substances.
Updated on: Jun 16, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.